GlaxoSmithKline could cut up to 60 workers at U.K. site as it ends production of antibiotic chemical
GlaxoSmithKline is shaking up its antibiotics business after at least one failed attempt to divest products. Now, dozens of GSK employees could be cut.
GSK is looking to trim positions at its Irvine, U.K., manufacturing facility as it phases out production of chemical 6-APA, a precursor for amoxicillin. The facility has around 325 total employees and up to 60 positions could be at risk.
